Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GABRP | O00591 | 2/20 | 0.31 |
| ▸ | GABRD | O14764 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541064 | 0.98 | ALDH1A1 (0.45) | ALDH1A1TSHRTHRBNOS3NOS1 | |
| SCHEMBL19852653 | 0.80 | ALDH1A1 (0.41) | ALDH1A1TSHRTHRB | |
| SCHEMBL30065241 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL2329737 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRBNOS3NOS1 | |
| SCHEMBL6363592 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRBMEN1KMT2A | |
| SCHEMBL648887 | 0.78 | NOS3 (0.54) | ALDH1A1TSHRTHRBNOS3NOS1 | |
| SCHEMBL15992736 | 0.78 | NOS3 (0.54) | ALDH1A1TSHRTHRBNOS3NOS1 | |
| SCHEMBL25660616 | 0.78 | NOS3 (0.57) | ALDH1A1TSHRNOS3NOS1NOS2 | |
| SCHEMBL303947 | 0.77 | — | — | |
| SCHEMBL10808653 | 0.77 | ALDH1A1 (0.45) | ALDH1A1TSHRTHRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4213808-A1 | METHODS OF TREATING EYE DISORDERS | Apellis Pharmaceuticals, Inc. (US) | 2023-07-26 | — | — | EP | claimed |
| WO-2020257779-A1 | HYDROXYMETHYL-MODIFIED GAMMA-PNA COMPOSITIONS AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2020-12-24 | — | — | WO | claimed |
| EP-3606465-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | Apellis Pharmaceuticals, Inc. (US) | 2020-02-12 | — | — | EP | claimed |
| EP-3526328-A1 | COMBINATION THERAPY FOR C3 INHIBITION | Apellis Pharmaceuticals, Inc. (US) | 2019-08-21 | — | — | EP | claimed |
| WO-2018187813-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. (US) | 2018-10-11 | — | — | WO | claimed |
| WO-2018075373-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2018-04-26 | — | — | WO | claimed |
| EP-2616808-A2 | PROLYL ENDOPEPTIDASE PROBES | SRI International (US) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037044-A2 | PROLYL ENDOPEPTIDASE PROBES | SRI INTERNATIONAL (US) | 2012-03-22 | — | — | WO | claimed |
| WO-2024249664-A2 | AFFINITY PURIFICATION METHODS FOR ADENO ASSOCIATED VIRUSES (AAVS) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2023212503-A1 | SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY | UNIVERSITY OF CONNECTICUT (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212504-A1 | SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY | UNIVERSITY OF CONNECTICUT (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4259188-A2 | PEPTIDE THERAPEUTICS FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | The Board of Regents of the University of Oklahoma (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023081318-A2 | COMPLEMENT INHIBITOR DOSING REGIMENS | APELLIS PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022125606-A2 | PEPTIDE THERAPEUTICS FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2012155107-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012138941-A1 | COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012078559-A2 | SMALL-MOLECULE HYDROPHOBIC TAGGING OF FUSION PROTEINS AND INDUCED DEGRADATION OF SAME | YALE UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012037044-A2 | PROLYL ENDOPEPTIDASE PROBES | SRI INTERNATIONAL (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011133948-A2 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20080267882-A1 | Multimeric RGD (arginine-glycine-aspartic acid (Arg-Gly-Asp)) peptide; positron emission tomography; angiogenesis; kits | STANFORD UNIVERSITY (US) | 2008-10-30 | — | — | US | disclosed |